Sino Biopharmaceutical Statistics
Total Valuation
Sino Biopharmaceutical has a market cap or net worth of HKD 58.80 billion. The enterprise value is 65.01 billion.
Market Cap | 58.80B |
Enterprise Value | 65.01B |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
Earnings Date | Mar 27, 2025 |
Ex-Dividend Date | Sep 10, 2024 |
Share Statistics
Sino Biopharmaceutical has 18.21 billion shares outstanding. The number of shares has decreased by -2.25% in one year.
Current Share Class | n/a |
Shares Outstanding | 18.21B |
Shares Change (YoY) | -2.25% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 49.69% |
Owned by Institutions (%) | 17.38% |
Float | 9.16B |
Valuation Ratios
The trailing PE ratio is 25.89 and the forward PE ratio is 17.72. Sino Biopharmaceutical's PEG ratio is 1.26.
PE Ratio | 25.89 |
Forward PE | 17.72 |
PS Ratio | 2.00 |
PB Ratio | 1.67 |
P/TBV Ratio | 1.84 |
P/FCF Ratio | 9.51 |
P/OCF Ratio | n/a |
PEG Ratio | 1.26 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.52, with an EV/FCF ratio of 10.52.
EV / Earnings | 14.79 |
EV / Sales | 2.18 |
EV / EBITDA | 9.52 |
EV / EBIT | 11.06 |
EV / FCF | 10.52 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.23.
Current Ratio | 1.15 |
Quick Ratio | 0.94 |
Debt / Equity | 0.23 |
Debt / EBITDA | 1.43 |
Debt / FCF | 1.68 |
Interest Coverage | 16.51 |
Financial Efficiency
Return on equity (ROE) is 12.87% and return on invested capital (ROIC) is 7.35%.
Return on Equity (ROE) | 12.87% |
Return on Assets (ROA) | 5.54% |
Return on Capital (ROIC) | 7.35% |
Revenue Per Employee | 1.22M |
Profits Per Employee | 179,852 |
Employee Count | 25,806 |
Asset Turnover | 0.42 |
Inventory Turnover | 2.72 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.21% in the last 52 weeks. The beta is 0.72, so Sino Biopharmaceutical's price volatility has been lower than the market average.
Beta (5Y) | 0.72 |
52-Week Price Change | +2.21% |
50-Day Moving Average | 3.39 |
200-Day Moving Average | 3.10 |
Relative Strength Index (RSI) | 44.52 |
Average Volume (20 Days) | 46,430,835 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of HKD 29.86 billion and earned 4.40 billion in profits. Earnings per share was 0.24.
Revenue | 29.86B |
Gross Profit | 24.24B |
Operating Income | 6.31B |
Pretax Income | 6.41B |
Net Income | 4.40B |
EBITDA | 7.20B |
EBIT | 6.31B |
Earnings Per Share (EPS) | 0.24 |
Balance Sheet
The company has 14.16 billion in cash and 10.40 billion in debt, giving a net cash position of 3.76 billion or 0.21 per share.
Cash & Cash Equivalents | 14.16B |
Total Debt | 10.40B |
Net Cash | 3.76B |
Net Cash Per Share | 0.21 |
Equity (Book Value) | 45.26B |
Book Value Per Share | 1.94 |
Working Capital | 3.52B |
Cash Flow
In the last 12 months, operating cash flow was 6.96 billion and capital expenditures -775.15 million, giving a free cash flow of 6.18 billion.
Operating Cash Flow | 6.96B |
Capital Expenditures | -775.15M |
Free Cash Flow | 6.18B |
FCF Per Share | 0.34 |
Margins
Gross margin is 81.16%, with operating and profit margins of 21.12% and 14.72%.
Gross Margin | 81.16% |
Operating Margin | 21.12% |
Pretax Margin | 21.48% |
Profit Margin | 14.72% |
EBITDA Margin | 24.11% |
EBIT Margin | 21.12% |
FCF Margin | 20.70% |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.85%.
Dividend Per Share | 0.06 |
Dividend Yield | 1.85% |
Dividend Growth (YoY) | -25.00% |
Years of Dividend Growth | n/a |
Payout Ratio | 15.47% |
Buyback Yield | 2.25% |
Shareholder Yield | 4.11% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.
Last Split Date | Jul 20, 2020 |
Split Type | Forward |
Split Ratio | 1.5 |
Scores
Sino Biopharmaceutical has an Altman Z-Score of 2.71. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.71 |
Piotroski F-Score | n/a |